This Program Grant has three investigators, Professor Denis Moss, Dr Rajiv Khanna and Dr Scott Burrows, each of whom has collaborated on two previous Program Grants. The group is well known in the area of herpesvirus immunology and have published numerous scientific papers in leading medical journals. This program grant focuses on two human herpesviruses. The first is called Epstein-Barr virus which causes glandular fever and is associated with arange of human cancers. The second virus is human ....This Program Grant has three investigators, Professor Denis Moss, Dr Rajiv Khanna and Dr Scott Burrows, each of whom has collaborated on two previous Program Grants. The group is well known in the area of herpesvirus immunology and have published numerous scientific papers in leading medical journals. This program grant focuses on two human herpesviruses. The first is called Epstein-Barr virus which causes glandular fever and is associated with arange of human cancers. The second virus is human cytomegalovirus which can cause birth defects and problems in transplant patients. In this program we are investigating how the body�s immune system controls these viruses to exploit this information to develop new treatments.Read moreRead less
The Molecular Basis Of Bacterial Infectious Diseases
Funder
National Health and Medical Research Council
Funding Amount
$16,230,996.00
Summary
Bacterial infectious diseases are a serious threat to human health, accounting for over 10 million deaths each year. This multidisciplinary collaborative team is investigating the complex interactions between major disease-causing bacteria and their human hosts, in order to determine how they cause disease. These studies will make a major contribution to fundamental knowledge in this field. This information is also essential for the development of cheaper and more effective vaccines, as well as ....Bacterial infectious diseases are a serious threat to human health, accounting for over 10 million deaths each year. This multidisciplinary collaborative team is investigating the complex interactions between major disease-causing bacteria and their human hosts, in order to determine how they cause disease. These studies will make a major contribution to fundamental knowledge in this field. This information is also essential for the development of cheaper and more effective vaccines, as well as novel drugs. These are urgently needed to reduce death and illness due to bacterial infectious diseases in the 21st century. 11Read moreRead less
This program application seeks to draw on the skills of a world leading group of Australian researchers to bring novel HIV vaccine designs to clinical trials, improve vaccine design and create new opportunities for commercialisation. The Chief Investigators, Prof David Cooper, Prof Peter Doherty (Nobel Prize winner), A-Prof Stephen Kent and Prof Ian Ramshaw, have achieved major scientific developments including: innovative collaborative clinical trials, cutting edge research in T cell immunology ....This program application seeks to draw on the skills of a world leading group of Australian researchers to bring novel HIV vaccine designs to clinical trials, improve vaccine design and create new opportunities for commercialisation. The Chief Investigators, Prof David Cooper, Prof Peter Doherty (Nobel Prize winner), A-Prof Stephen Kent and Prof Ian Ramshaw, have achieved major scientific developments including: innovative collaborative clinical trials, cutting edge research in T cell immunology, the establishment of the only PC3-level nonhuman primate facility in the Southern hemisphere, T cell immunogenicity of the DNA-viral vector prime-boost vaccine regimens and ground-breaking research on cytokine co-expressing viral vector vaccines. The Principle Investigators also have a record of substantial achievement in relation to HIV and T cell biology as well as novel vaccination technologies. There is a strong history of successful collaboration among this group leading to the award of major NIH funding.Read moreRead less
The development of vaccines and better treatments for HIV-AIDS and Hepatitis C are urgent global health priorities. This Program will undertake studies to better understand effective immunity against HIV and hepatitis C, allowing the rational design and testing of novel vaccines and treatments. The Program brings together a team of researchers with skills in basic virology and immunology with those providing expertise in translating findings in the laboratory into human clinical trials.
Malaria: From Target Identification And Therapeutics
Funder
National Health and Medical Research Council
Funding Amount
$5,276,440.00
Summary
The team brings together a number of experts in various aspects of malaria, vaccines and drug design to develop new therapeutic approaches to control of one of the world�s major infectious diseases. Recent developments such as the complete sequence of every malaria gene provides an unparalleled opportunity to use a number of powerful new techniques in biology to identify vulnerabilities in the parasite that may be targeted. Members of the team include Professor von Itzstein who was responsible f ....The team brings together a number of experts in various aspects of malaria, vaccines and drug design to develop new therapeutic approaches to control of one of the world�s major infectious diseases. Recent developments such as the complete sequence of every malaria gene provides an unparalleled opportunity to use a number of powerful new techniques in biology to identify vulnerabilities in the parasite that may be targeted. Members of the team include Professor von Itzstein who was responsible for the design of the anti-flu drug Relenza, Professor Ross Coppel who is a pioneer in the application of molecular biology to the study of malaria, and Drs Cooke and Plebanski, exciting and talented young scientists who already have made highly significant and important contributions to our understanding of how malaria parasites function and cause disease. Success in this research program has the capacity to save millions of lives each year by preventing the deadly toll of this important human scourge.Read moreRead less
Immunological Therapies For Cancer And Autoimmunity
Funder
National Health and Medical Research Council
Funding Amount
$4,928,323.00
Summary
The programme team comprises a group of leading scientists with a history of successful investigation into the mechanisms and treatment of diseases in which the immune system plays a role in their development. These include cancers of the cervix and blood system, and autoimmune diseases such as rheumatoid arthritis and type 1 diabetes. Working together, the team have made discoveries that have led to testing and clinical development of new treatments for these diseases. In this programme, the te ....The programme team comprises a group of leading scientists with a history of successful investigation into the mechanisms and treatment of diseases in which the immune system plays a role in their development. These include cancers of the cervix and blood system, and autoimmune diseases such as rheumatoid arthritis and type 1 diabetes. Working together, the team have made discoveries that have led to testing and clinical development of new treatments for these diseases. In this programme, the team aims to discover mechanisms regulating the immune response, and to exploit this knowledge to define new ways of switching on or off, specific immune responses. We will particularly seek to develop novel vaccines for chronic infections and autoimmune diseases, and to improve the safety of bone marrow transplantation.Read moreRead less
The Translation Of Dendritic Cell Biology Into Clinical Practice
Funder
National Health and Medical Research Council
Funding Amount
$3,674,406.00
Summary
This Program combines world recognized expertise in the science of immunology and the blood system, with top Australian expertise in the practice of bone marrow transplantation and the treatment of hematological malignancies. Its vision is to study the biology of dendritic cells, which are the specialized white cells that initiate the immune response, and then, to apply this knowledge to the design and introduction of novel diagnostic and therapeutic immune strategies, to improve the survival of ....This Program combines world recognized expertise in the science of immunology and the blood system, with top Australian expertise in the practice of bone marrow transplantation and the treatment of hematological malignancies. Its vision is to study the biology of dendritic cells, which are the specialized white cells that initiate the immune response, and then, to apply this knowledge to the design and introduction of novel diagnostic and therapeutic immune strategies, to improve the survival of patients with leukaemia, lymphoma and multiple myeloma.Read moreRead less
Molecular Determinants Of Risk, Progression And Treatment Response In Melanoma
Funder
National Health and Medical Research Council
Funding Amount
$8,381,820.00
Summary
Melanoma is a major Australian health problem. NSW figures for 2002 show it to be the second most common cancer in men and women. It has a disproportionately heavy impact on productive years of the life of young Australians because it is the commonest cancer in those aged 15-45 years. The investigators are all associated with the Sydney Melanoma Unit (SMU), the world�s largest clinical service dedicated to the treatment of melanoma, treating >1200 new melanoma patients annually. We have also ....Melanoma is a major Australian health problem. NSW figures for 2002 show it to be the second most common cancer in men and women. It has a disproportionately heavy impact on productive years of the life of young Australians because it is the commonest cancer in those aged 15-45 years. The investigators are all associated with the Sydney Melanoma Unit (SMU), the world�s largest clinical service dedicated to the treatment of melanoma, treating >1200 new melanoma patients annually. We have also recruited large cohorts of individuals with high susceptibility to melanoma, both familial and population-based, throughout southeastern Australia. We aim to utilise these unique, internationally-recognised resources to develop a scientific basis for 1) improved management of individuals at high risk for development and progression of melanoma, and 2) improved treatment of patients with early and disseminated melanoma. We will base this on consolidation of existing collaborative research into molecular predictors of risk, progression and treatment response in melanoma.Read moreRead less